CARLSBAD, CA--(Marketwire - Jan 3, 2013) - International Stem Cell Corporation (OTCQB: [ ISCO ]) ([ www.internationalstemcell.com ]) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that Executive Vice President, Dr. Simon Craw, will present at the Biotech Showcase™ 2013 on Monday, January 7th at 9:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.

Biotech Showcase 2013 conference presentation details:
Date: Monday, January 7, 2013
Time: 9:30 pm PST
Location: Parc 55 Wyndham Union Square Hotel, San Francisco, CA
Room: Room Mission II - Track C
Conference details: [ http://www.ebdgroup.com/bts/index.php ]

Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team. To register for the event, please visit the conference website at [ www.ebdgroup.com/bts/registration/index.php ].

You may also contact Mark McPartland with MZ Group via email [ markmcp@mzgroup.us ] or phone 212-301-7130 to arrange a meeting with management at the conference.

Biotech Showcase™ 2013 is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year. For more information, please visit the conference website at [ http://www.ebdgroup.com/bts/index.php ]

Additional information and the investor presentation will be available on the investor relations section of the Company's website [ www.internationalstemcell.com ].

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ([ www.lifelinecelltech.com ]), and stem cell-based skin care products through its subsidiary Lifeline Skin Care ([ www.lifelineskincare.com ]). More information is available at [ www.internationalstemcell.com ].

To receive ongoing corporate communications via email, visit: [ http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 ]

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: [ www.facebook.com/InternationalStemCellCorporation ] and [ www.twitter.com/intlstemcell ]

Safe harbor statement

Statements pertaining to anticipated developments, scientific program and clinical development goals and plans, potential sales growth, new products and distribution channels and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.